Cardiologia Italiana del Territorio

Novità’ dalla letteratura

//Novità’ dalla letteratura
- 06/2016

Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary

giugno 2016|News, Novità’ dalla letteratura|0 Comments

In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants (NOACs) in patients with atrial fibrillation (AF) (Heidbuchel H, Verhamme P, Alings M, Antz M, Hacke W, Oldgren J, Sinnaeve P, Camm AJ, Kirchhof P, European Heart Rhythm A. European Heart Rhythm Association Practical Guide on

- 06/2016

Reduction in Ischemic Events With Ticagrelor in Diabetic Patients With Prior Myocardial Infarction in PEGASUS–TIMI 54

giugno 2016|News, Novità’ dalla letteratura|0 Comments

Background  Patients with diabetes appear to be at elevated risk of atherothrombotic events. Objectives  The purpose of this study was to determine the effect of antiplatelet therapy with ticagrelor on recurrent ischemic events in patients with diabetes and prior myocardial infarction (MI). Methods  We examined the subgroups of patients with diabetes (n = 6,806) and without

- 06/2016

Long-Term Population-Based Cerebral Ischemic Event and Cognitive Outcomes of Direct Oral Anticoagulants Compared With Warfarin Among Long-term Anticoagulated Patients for Atrial Fibrillation

giugno 2016|News, Novità’ dalla letteratura|0 Comments

Direct oral anticoagulants (DOACs) have been used in clinical practice in the United States for the last 4 to 6 years. Although DOACs may be an attractive alternative to warfarin in many patients, long-term outcomes of use of these medications are unknown. We performed a propensity-matched analysis to report patient important outcomes of death, stroke/transient ischemic

- 05/2016

Presentazione del progetto FACT sulla Fibrillazione atriale

maggio 2016|News, Novità’ dalla letteratura|0 Comments

  Cari soci Ance ho il piacere e l’onore , come anticipato alla riunione dei nostri quadri tenutasi il 22/23 aprile , di comunicarvi l’avvio di un importante studio, in cooperazione con l’AIAC, sulla fibrillazione atriale: lo studio FACT . A fine maggio partiranno in quattro regioni ( Sardegna ,Triveneto, Sicilia e Campania ) le

- 04/2016

A New Electrocardiographic Marker of Sudden Death in Brugada SyndromeThe S-Wave in Lead I

aprile 2016|News, Novità’ dalla letteratura|0 Comments

Abstract Background  Risk stratification in asymptomatic patients remains by far the most important yet unresolved clinical problem in the Brugada syndrome (BrS). Objectives  This study sought to analyze the usefulness of electrocardiographic parameters as markers of sudden cardiac death (SCD) in BrS. Methods  This study analyzed data from 347 consecutive patients (78.4% male; mean age

- 04/2016

Duration of Dual Antiplatelet Therapy: A Systematic Review for the 2016 ACC/AHA Guideline Focused Update on Duration of Dual Antiplatelet Therapy in Patients With Coronary Artery Disease

aprile 2016|Linee guida, News, Novità’ dalla letteratura|0 Comments

A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines Abstract Background: The optimal duration of dual antiplatelet therapy (DAPT) after implantation of newer- generation drug-eluting stents (DES) remains uncertain. Similarly, questions remain about the role of DAPT in long-term therapy of stable post–myocardial infarction (MI) patients. Aim: Our

- 04/2016

Clinical Diagnosis of Electrical vs Anatomic Left Ventricular Hypertrophy

aprile 2016|News, Novità’ dalla letteratura|0 Comments

Most physician readers of Aro’s and Chugh’s elegant review of electrical and anatomic types of LVH and the implications will be puzzled by the concepts that electrical LVH (ECG/LVH) and anatomic LVH (echo/LVH and MRI/LVH) might be different entities, and that patients may have one form without the other. These concepts have been evolving over

- 04/2016

Prognostic Usefulness of Proenkephalin in Stable Ambulatory Patients With Heart Failure

aprile 2016|Cardiologia: presente e futuro... Discutiamone, News, Novità’ dalla letteratura|0 Comments

Patients with heart failure have a poor prognosis, yet outcomes might be improved by early identification of risk. Proenkephalin (proENK), a novel biomarker, is a stable surrogate marker for endogenous enkephalins and is an independent predictor of heart failure and death in patients who had an acute myocardial infarction. This is the first study to

- 03/2016

Parere positivo Fda all’antiaggregante vorapaxar dopo un infarto del miocardio.

marzo 2016|News, Novità’ dalla letteratura|0 Comments

Dopo l’endorsement dei giorni scorsi ricevuto dello staff interno dell’Fda, lo scorso 15 gennaio il nuovo antiaggregante orale vorapaxar ha ricevuto il parere positivo  degli esperti del Cardiovascular and Renal Drugs Advisory Committee dell’Fda. Con 10 voti a 1, gli esperti ne hanno raccomandato l’approvazione come terapia antiaggregante aggiuntiva a quella standard (ASA o ASA

- 02/2016

Long-Term Outcome of Incomplete Revascularization After PCI

febbraio 2016|News, Novità’ dalla letteratura|0 Comments

Objectives  The aim of this study was to describe current practice regarding completeness of revascularization in patients with multivessel disease undergoing percutaneous coronary intervention (PCI) and to investigate the association of incomplete revascularization (IR) with death, repeat revascularization, and myocardial infarction (MI) in a large nationwide registry. Background  The benefits of multivessel PCI are controversial.